Boehringer Ingelheim 2015 sales up over 11% in euro terms

19 April 2016
boehringer-ingelheim-big

In 2015, family-owned German pharma major Boehringer Ingelheim generated net sales of 14.8 billion euros, representing an increase of 4.1% in currency-adjusted terms (+11.1 % in euro terms).

Excluding the generics business, which was sold at the beginning of 2016, currency-adjusted net sales rose by 5.3%. Since operating income also improved by 6% to 2.3 billion euros, the return on net sales came to 15.3%.

With net sales of over 3.5 billion euros, the respiratory medication Spiriva (tiotropium) remains the best-selling medicine. The company’s diabetes business has established itself as a long-term growth driver, with net sales for the entire diabetes portfolio increasing significantly by around 49% in currency-adjusted terms to 1.1 billion euros (+63.8% in euro terms). The anticoagulant Pradaxa (dabigatran) contributed around 1.3 billion euros to net sales. Boehringer Ingelheim generated around 10% of its total net sales from consumer health care medicines in 2015.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical